Market Outlook
The global Acute Migraine Drugs market size was valued at USD 2165.3 million in 2022 and is forecast to a readjusted size of USD 3473.9 million by 2029 with a CAGR of 7.0% during review period.
A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.
The top 3 manufacturers held about 29.5% of the market share in 2019, while top 5 hold 41.93%.
This report is a detailed and comprehensive analysis for global Acute Migraine Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Acute Migraine Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (USD/Unit), 2018-2029
Global Acute Migraine Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (USD/Unit), 2018-2029
Global Acute Migraine Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (USD/Unit), 2018-2029
Global Acute Migraine Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Unit), and ASP (USD/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Acute Migraine Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Acute Migraine Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Key Market Players
GSK
Teva
Pfizer
Novartis
Sun Pharma
Grunenthal
Endo Pharmaceuticals
Merck
J & J
Segmentation By Type
Triptans
NSAIDs
Others
Segmentation By Application
Hospital Pharmacies
Drug Stores
Segmentation By Region
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Market SWOT Analysis
What are the strengths of the Acute Migraine Drugs Market in 2025?
The Acute Migraine Drugs Market in 2025 will benefit from increasing awareness about migraine treatments, enhanced drug formulations with fewer side effects, and improved patient outcomes through innovative treatment options like CGRP inhibitors. The growth in demand for effective, fast-acting drugs will also drive market expansion.
What are the weaknesses of the Acute Migraine Drugs Market in 2025?
One weakness is the high cost of newer migraine treatments, which could limit access for a significant portion of the population. Additionally, there may be challenges in developing treatments for patients who do not respond to current therapies, creating a gap in effective management options.
What are the opportunities in the Acute Migraine Drugs Market in 2025?
There are opportunities for market growth through the development of combination therapies and personalized treatments that cater to different migraine triggers. Additionally, expanding access in emerging markets and leveraging telemedicine for remote treatment and diagnosis will further enhance market potential.
What are the threats to the Acute Migraine Drugs Market in 2025?
The market faces threats from the high competition within generic drugs, which could drive down prices for some treatment options. Regulatory challenges and long approval timelines for new drugs could also delay innovation. Furthermore, public healthcare policies may impose constraints on the availability of certain high-cost treatments.
Market PESTEL Analysis
What political factors could impact the Acute Migraine Drugs Market in 2025?
Political factors, including healthcare policies and government funding for research, can significantly influence the availability and accessibility of acute migraine drugs. Government regulations on drug pricing and reimbursement schemes may also impact the market, especially in regions with stringent healthcare policies.
How do economic factors affect the Acute Migraine Drugs Market in 2025?
Economic factors like the overall economic growth, healthcare expenditure, and income levels will play a key role in market expansion. In developed markets, higher disposable income can lead to greater spending on advanced migraine treatments, while in low-income regions, economic barriers may limit drug access.
What social factors are influencing the Acute Migraine Drugs Market in 2025?
Increasing awareness and understanding of migraines are driving demand for effective treatments. Social acceptance of pharmaceutical solutions and the rise of self-medication or over-the-counter options also influence market dynamics. Moreover, changing work patterns and stress levels are contributing to a rise in migraine incidence.
What technological advancements are affecting the Acute Migraine Drugs Market in 2025?
Technological innovations such as new drug delivery systems, digital health tools, and personalized medicine are expected to improve treatment outcomes. The development of biologics, including CGRP inhibitors, is one of the significant technological advancements, offering more targeted and effective treatment for acute migraines.
What environmental factors impact the Acute Migraine Drugs Market in 2025?
Environmental factors such as climate change and pollution may increase the frequency of migraines, indirectly boosting the demand for acute migraine treatments. Additionally, sustainability trends are pushing for greener drug manufacturing practices and packaging, influencing how companies operate in the market.
What legal factors could affect the Acute Migraine Drugs Market in 2025?
Legal factors include intellectual property laws, patent expirations, and the regulatory approval process for new drugs. The market could face shifts as patents expire on existing drugs, leading to an influx of generic products. Additionally, evolving drug regulations, especially related to safety and side effects, will continue to shape the market's landscape.
Market SIPOC Analysis
Who are the suppliers in the Acute Migraine Drugs Market in 2025?
Suppliers in the Acute Migraine Drugs Market include pharmaceutical companies that manufacture active ingredients, raw materials, and drug formulations. Additionally, contract manufacturers and distributors play a role in ensuring the availability of drugs in various regions.
Who are the inputs in the Acute Migraine Drugs Market in 2025?
The inputs include research and development resources, clinical trial data, regulatory approvals, and advanced technology for drug formulation and delivery. Financial investments, marketing strategies, and healthcare partnerships also contribute to the input process.
What processes are involved in the Acute Migraine Drugs Market in 2025?
Key processes in the Acute Migraine Drugs Market involve drug development, clinical testing, regulatory approval, manufacturing, distribution, and sales. Marketing and post-market surveillance for safety and effectiveness also play critical roles in ensuring continued product success.
Who are the customers in the Acute Migraine Drugs Market in 2025?
The customers include patients suffering from acute migraines, healthcare providers, hospitals, clinics, and pharmacies. Additionally, health insurance companies and governmental bodies that influence drug accessibility through reimbursement policies are also part of the customer base.
What are the outputs in the Acute Migraine Drugs Market in 2025?
The outputs are the acute migraine drugs available to patients, which include prescription medications like triptans, CGRP inhibitors, and over-the-counter treatments. These products are designed to relieve symptoms and improve the quality of life for those affected by migraines.
Market Porter's Five Forces
What is the threat of new entrants in the Acute Migraine Drugs Market in 2025?
The threat of new entrants is moderate in the Acute Migraine Drugs Market. While the high demand for effective treatments attracts new players, the significant capital investment required for R&D, clinical trials, and regulatory approvals acts as a barrier. Additionally, established brands with patents hold a competitive edge.
How intense is the rivalry among existing competitors in the Acute Migraine Drugs Market in 2025?
The rivalry among existing competitors is high, as several well-established pharmaceutical companies dominate the market. Companies compete on the development of new, more effective treatments, pricing, and access to healthcare providers and patients. The introduction of generics also increases competition.
What is the bargaining power of suppliers in the Acute Migraine Drugs Market in 2025?
The bargaining power of suppliers is moderate. While raw materials and active pharmaceutical ingredients are essential, there are multiple suppliers available, reducing individual supplier power. However, the reliance on specialized materials for advanced drug formulations can give certain suppliers more leverage.
What is the bargaining power of buyers in the Acute Migraine Drugs Market in 2025?
The bargaining power of buyers is increasing as more generic options become available and healthcare providers seek cost-effective solutions. Patients and healthcare systems have more influence over pricing and access to treatments, particularly in regions with government-run healthcare or insurance-based systems.
What is the threat of substitute products in the Acute Migraine Drugs Market in 2025?
The threat of substitutes is moderate. While alternative treatments like lifestyle changes, non-prescription pain relievers, and herbal remedies exist, they often do not provide the same level of effectiveness as prescription drugs. However, the growing trend toward natural or non-pharmaceutical remedies may increase competition for drug-based treatments.
Market Upstream Analysis
What are the key upstream factors influencing the Acute Migraine Drugs Market in 2025?
The key upstream factors include the availability of high-quality raw materials for drug production, advancements in drug formulation technologies, and strong research and development investments by pharmaceutical companies. Collaborations with research institutions and biotech firms also play a crucial role in driving innovation.
How does research and development impact the Acute Migraine Drugs Market in 2025?
Research and development are critical upstream drivers, as the market relies on breakthroughs in drug efficacy, delivery systems, and safety profiles. Continuous R&D leads to the development of novel treatments, such as CGRP inhibitors and other biologics, offering new options for patients with unmet needs.
What role do regulatory bodies play in the Acute Migraine Drugs Market in 2025?
Regulatory bodies, such as the FDA and EMA, significantly impact the upstream side of the market by determining the approval process for new drugs. Their regulations on clinical trials, drug safety, and labeling influence drug manufacturers’ timelines and costs, affecting market dynamics.
How do suppliers of active pharmaceutical ingredients (APIs) affect the Acute Migraine Drugs Market in 2025?
Suppliers of APIs are crucial in ensuring the consistent quality and availability of ingredients needed for acute migraine treatments. The cost, quality, and supply chain efficiency of these APIs directly impact drug pricing, availability, and manufacturing timelines in the market.
What are the technological advancements affecting the upstream sector of the Acute Migraine Drugs Market in 2025?
Technological advancements, such as precision medicine, digital health tools for better diagnosis, and advancements in drug delivery mechanisms, influence the upstream sector. These innovations enhance the effectiveness and patient compliance with migraine treatments, driving demand for new solutions.
Market Midstream Analysis
What are the key midstream factors influencing the Acute Migraine Drugs Market in 2025?
Key midstream factors include the production processes, quality control, and manufacturing capabilities of pharmaceutical companies. Efficient manufacturing and distribution networks are vital for ensuring the timely availability of migraine drugs in various regions, especially in global markets.
How do manufacturers affect the Acute Migraine Drugs Market in 2025?
Manufacturers play a significant role in the market by ensuring the scalability of production, compliance with regulatory standards, and maintaining the safety and efficacy of migraine drugs. Their ability to innovate in terms of drug delivery mechanisms and formulations also impacts product offerings in the market.
How do distribution channels impact the Acute Migraine Drugs Market in 2025?
Distribution channels, including wholesalers, pharmacies, and hospitals, are crucial in ensuring that migraine drugs reach patients efficiently. The expansion of e-commerce and online pharmacies is also reshaping the distribution landscape, making treatments more accessible to a broader audience.
What role do healthcare providers play in the Midstream of the Acute Migraine Drugs Market in 2025?
Healthcare providers, including physicians and neurologists, are central to prescribing the right treatments to patients. Their expertise, along with growing awareness of newer treatment options, helps drive demand for advanced migraine drugs in the market.
How do pricing strategies affect the Midstream sector of the Acute Migraine Drugs Market in 2025?
Pricing strategies, including discounts, insurance reimbursements, and pricing of newer biologics, directly influence the midstream dynamics. Competitive pricing and patient affordability will drive access to treatments, especially in regions with varying economic conditions.
Market Downstream Analysis
What are the key downstream factors influencing the Acute Migraine Drugs Market in 2025?
Key downstream factors include patient access to treatments, physician prescribing patterns, and patient adherence to prescribed therapies. The effectiveness of distribution systems in reaching end consumers and the role of insurance coverage in making drugs affordable are also critical in shaping market dynamics.
How do end consumers influence the Acute Migraine Drugs Market in 2025?
End consumers, particularly migraine sufferers, directly drive demand for effective, fast-acting treatments. Their preferences for certain drug formulations, such as oral versus injectable medications, and the growing trend of self-medication also influence market trends.
What role do insurance providers play in the Downstream sector of the Acute Migraine Drugs Market in 2025?
Insurance providers play a crucial role in determining access to migraine drugs by dictating reimbursement policies and covering drug costs. The extent of coverage, particularly for expensive treatments like biologics, significantly impacts patient access to advanced therapies.
How do marketing and promotional strategies affect the Downstream sector of the Acute Migraine Drugs Market in 2025?
Effective marketing strategies, including direct-to-consumer advertising, physician education, and partnerships with healthcare providers, help increase awareness and drive demand for new migraine treatments. Promotional efforts will also play a role in positioning innovative drugs in a competitive market.
How do patient support programs impact the Acute Migraine Drugs Market in 2025?
Patient support programs, such as assistance with insurance claims, providing educational materials, and ensuring proper medication adherence, improve patient outcomes. These programs help reduce dropout rates from treatment regimens, thus enhancing the effectiveness and loyalty to specific migraine drugs.
Chapter 1, to describe Acute Migraine Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Acute Migraine Drugs, with price, sales, revenue and global market share of Acute Migraine Drugs from 2018 to 2023.
Chapter 3, the Acute Migraine Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Acute Migraine Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Acute Migraine Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Acute Migraine Drugs.
Chapter 14 and 15, to describe Acute Migraine Drugs sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Acute Migraine Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Acute Migraine Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Triptans
1.3.3 NSAIDs
1.3.4 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Acute Migraine Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital Pharmacies
1.4.3 Drug Stores
1.5 Global Acute Migraine Drugs Market Size & Forecast
1.5.1 Global Acute Migraine Drugs Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Acute Migraine Drugs Sales Quantity (2018-2029)
1.5.3 Global Acute Migraine Drugs Average Price (2018-2029)
2 Manufacturers Profiles
2.1 GSK
2.1.1 GSK Details
2.1.2 GSK Major Business
2.1.3 GSK Acute Migraine Drugs Product and Services
2.1.4 GSK Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 GSK Recent Developments/Updates
2.2 Teva
2.2.1 Teva Details
2.2.2 Teva Major Business
2.2.3 Teva Acute Migraine Drugs Product and Services
2.2.4 Teva Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Teva Recent Developments/Updates
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Acute Migraine Drugs Product and Services
2.3.4 Pfizer Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfizer Recent Developments/Updates
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Acute Migraine Drugs Product and Services
2.4.4 Novartis Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Novartis Recent Developments/Updates
2.5 Sun Pharma
2.5.1 Sun Pharma Details
2.5.2 Sun Pharma Major Business
2.5.3 Sun Pharma Acute Migraine Drugs Product and Services
2.5.4 Sun Pharma Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Sun Pharma Recent Developments/Updates
2.6 Grunenthal
2.6.1 Grunenthal Details
2.6.2 Grunenthal Major Business
2.6.3 Grunenthal Acute Migraine Drugs Product and Services
2.6.4 Grunenthal Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Grunenthal Recent Developments/Updates
2.7 Endo Pharmaceuticals
2.7.1 Endo Pharmaceuticals Details
2.7.2 Endo Pharmaceuticals Major Business
2.7.3 Endo Pharmaceuticals Acute Migraine Drugs Product and Services
2.7.4 Endo Pharmaceuticals Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Endo Pharmaceuticals Recent Developments/Updates
2.8 Merck
2.8.1 Merck Details
2.8.2 Merck Major Business
2.8.3 Merck Acute Migraine Drugs Product and Services
2.8.4 Merck Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Merck Recent Developments/Updates
2.9 J & J
2.9.1 J & J Details
2.9.2 J & J Major Business
2.9.3 J & J Acute Migraine Drugs Product and Services
2.9.4 J & J Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 J & J Recent Developments/Updates
3 Competitive Environment: Acute Migraine Drugs by Manufacturer
3.1 Global Acute Migraine Drugs Sales Quantity by Manufacturer (2018-2023)
3.2 Global Acute Migraine Drugs Revenue by Manufacturer (2018-2023)
3.3 Global Acute Migraine Drugs Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Acute Migraine Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Acute Migraine Drugs Manufacturer Market Share in 2022
3.4.2 Top 6 Acute Migraine Drugs Manufacturer Market Share in 2022
3.5 Acute Migraine Drugs Market: Overall Company Footprint Analysis
3.5.1 Acute Migraine Drugs Market: Region Footprint
3.5.2 Acute Migraine Drugs Market: Company Product Type Footprint
3.5.3 Acute Migraine Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Acute Migraine Drugs Market Size by Region
4.1.1 Global Acute Migraine Drugs Sales Quantity by Region (2018-2029)
4.1.2 Global Acute Migraine Drugs Consumption Value by Region (2018-2029)
4.1.3 Global Acute Migraine Drugs Average Price by Region (2018-2029)
4.2 North America Acute Migraine Drugs Consumption Value (2018-2029)
4.3 Europe Acute Migraine Drugs Consumption Value (2018-2029)
4.4 Asia-Pacific Acute Migraine Drugs Consumption Value (2018-2029)
4.5 South America Acute Migraine Drugs Consumption Value (2018-2029)
4.6 Middle East and Africa Acute Migraine Drugs Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Acute Migraine Drugs Sales Quantity by Type (2018-2029)
5.2 Global Acute Migraine Drugs Consumption Value by Type (2018-2029)
5.3 Global Acute Migraine Drugs Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Acute Migraine Drugs Sales Quantity by Application (2018-2029)
6.2 Global Acute Migraine Drugs Consumption Value by Application (2018-2029)
6.3 Global Acute Migraine Drugs Average Price by Application (2018-2029)
7 North America
7.1 North America Acute Migraine Drugs Sales Quantity by Type (2018-2029)
7.2 North America Acute Migraine Drugs Sales Quantity by Application (2018-2029)
7.3 North America Acute Migraine Drugs Market Size by Country
7.3.1 North America Acute Migraine Drugs Sales Quantity by Country (2018-2029)
7.3.2 North America Acute Migraine Drugs Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Acute Migraine Drugs Sales Quantity by Type (2018-2029)
8.2 Europe Acute Migraine Drugs Sales Quantity by Application (2018-2029)
8.3 Europe Acute Migraine Drugs Market Size by Country
8.3.1 Europe Acute Migraine Drugs Sales Quantity by Country (2018-2029)
8.3.2 Europe Acute Migraine Drugs Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Acute Migraine Drugs Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Acute Migraine Drugs Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Acute Migraine Drugs Market Size by Region
9.3.1 Asia-Pacific Acute Migraine Drugs Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Acute Migraine Drugs Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Acute Migraine Drugs Sales Quantity by Type (2018-2029)
10.2 South America Acute Migraine Drugs Sales Quantity by Application (2018-2029)
10.3 South America Acute Migraine Drugs Market Size by Country
10.3.1 South America Acute Migraine Drugs Sales Quantity by Country (2018-2029)
10.3.2 South America Acute Migraine Drugs Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Acute Migraine Drugs Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Acute Migraine Drugs Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Acute Migraine Drugs Market Size by Country
11.3.1 Middle East & Africa Acute Migraine Drugs Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Acute Migraine Drugs Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Acute Migraine Drugs Market Drivers
12.2 Acute Migraine Drugs Market Restraints
12.3 Acute Migraine Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Acute Migraine Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Acute Migraine Drugs
13.3 Acute Migraine Drugs Production Process
13.4 Acute Migraine Drugs Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Acute Migraine Drugs Typical Distributors
14.3 Acute Migraine Drugs Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Acute Migraine Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Acute Migraine Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. GSK Basic Information, Manufacturing Base and Competitors
Table 4. GSK Major Business
Table 5. GSK Acute Migraine Drugs Product and Services
Table 6. GSK Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. GSK Recent Developments/Updates
Table 8. Teva Basic Information, Manufacturing Base and Competitors
Table 9. Teva Major Business
Table 10. Teva Acute Migraine Drugs Product and Services
Table 11. Teva Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Teva Recent Developments/Updates
Table 13. Pfizer Basic Information, Manufacturing Base and Competitors
Table 14. Pfizer Major Business
Table 15. Pfizer Acute Migraine Drugs Product and Services
Table 16. Pfizer Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Pfizer Recent Developments/Updates
Table 18. Novartis Basic Information, Manufacturing Base and Competitors
Table 19. Novartis Major Business
Table 20. Novartis Acute Migraine Drugs Product and Services
Table 21. Novartis Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Novartis Recent Developments/Updates
Table 23. Sun Pharma Basic Information, Manufacturing Base and Competitors
Table 24. Sun Pharma Major Business
Table 25. Sun Pharma Acute Migraine Drugs Product and Services
Table 26. Sun Pharma Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Sun Pharma Recent Developments/Updates
Table 28. Grunenthal Basic Information, Manufacturing Base and Competitors
Table 29. Grunenthal Major Business
Table 30. Grunenthal Acute Migraine Drugs Product and Services
Table 31. Grunenthal Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Grunenthal Recent Developments/Updates
Table 33. Endo Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 34. Endo Pharmaceuticals Major Business
Table 35. Endo Pharmaceuticals Acute Migraine Drugs Product and Services
Table 36. Endo Pharmaceuticals Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Endo Pharmaceuticals Recent Developments/Updates
Table 38. Merck Basic Information, Manufacturing Base and Competitors
Table 39. Merck Major Business
Table 40. Merck Acute Migraine Drugs Product and Services
Table 41. Merck Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Merck Recent Developments/Updates
Table 43. J & J Basic Information, Manufacturing Base and Competitors
Table 44. J & J Major Business
Table 45. J & J Acute Migraine Drugs Product and Services
Table 46. J & J Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. J & J Recent Developments/Updates
Table 48. Global Acute Migraine Drugs Sales Quantity by Manufacturer (2018-2023) & (K Unit)
Table 49. Global Acute Migraine Drugs Revenue by Manufacturer (2018-2023) & (USD Million)
Table 50. Global Acute Migraine Drugs Average Price by Manufacturer (2018-2023) & (USD/Unit)
Table 51. Market Position of Manufacturers in Acute Migraine Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 52. Head Office and Acute Migraine Drugs Production Site of Key Manufacturer
Table 53. Acute Migraine Drugs Market: Company Product Type Footprint
Table 54. Acute Migraine Drugs Market: Company Product Application Footprint
Table 55. Acute Migraine Drugs New Market Entrants and Barriers to Market Entry
Table 56. Acute Migraine Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 57. Global Acute Migraine Drugs Sales Quantity by Region (2018-2023) & (K Unit)
Table 58. Global Acute Migraine Drugs Sales Quantity by Region (2024-2029) & (K Unit)
Table 59. Global Acute Migraine Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 60. Global Acute Migraine Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 61. Global Acute Migraine Drugs Average Price by Region (2018-2023) & (USD/Unit)
Table 62. Global Acute Migraine Drugs Average Price by Region (2024-2029) & (USD/Unit)
Table 63. Global Acute Migraine Drugs Sales Quantity by Type (2018-2023) & (K Unit)
Table 64. Global Acute Migraine Drugs Sales Quantity by Type (2024-2029) & (K Unit)
Table 65. Global Acute Migraine Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 66. Global Acute Migraine Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 67. Global Acute Migraine Drugs Average Price by Type (2018-2023) & (USD/Unit)
Table 68. Global Acute Migraine Drugs Average Price by Type (2024-2029) & (USD/Unit)
Table 69. Global Acute Migraine Drugs Sales Quantity by Application (2018-2023) & (K Unit)
Table 70. Global Acute Migraine Drugs Sales Quantity by Application (2024-2029) & (K Unit)
Table 71. Global Acute Migraine Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 72. Global Acute Migraine Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 73. Global Acute Migraine Drugs Average Price by Application (2018-2023) & (USD/Unit)
Table 74. Global Acute Migraine Drugs Average Price by Application (2024-2029) & (USD/Unit)
Table 75. North America Acute Migraine Drugs Sales Quantity by Type (2018-2023) & (K Unit)
Table 76. North America Acute Migraine Drugs Sales Quantity by Type (2024-2029) & (K Unit)
Table 77. North America Acute Migraine Drugs Sales Quantity by Application (2018-2023) & (K Unit)
Table 78. North America Acute Migraine Drugs Sales Quantity by Application (2024-2029) & (K Unit)
Table 79. North America Acute Migraine Drugs Sales Quantity by Country (2018-2023) & (K Unit)
Table 80. North America Acute Migraine Drugs Sales Quantity by Country (2024-2029) & (K Unit)
Table 81. North America Acute Migraine Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 82. North America Acute Migraine Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 83. Europe Acute Migraine Drugs Sales Quantity by Type (2018-2023) & (K Unit)
Table 84. Europe Acute Migraine Drugs Sales Quantity by Type (2024-2029) & (K Unit)
Table 85. Europe Acute Migraine Drugs Sales Quantity by Application (2018-2023) & (K Unit)
Table 86. Europe Acute Migraine Drugs Sales Quantity by Application (2024-2029) & (K Unit)
Table 87. Europe Acute Migraine Drugs Sales Quantity by Country (2018-2023) & (K Unit)
Table 88. Europe Acute Migraine Drugs Sales Quantity by Country (2024-2029) & (K Unit)
Table 89. Europe Acute Migraine Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 90. Europe Acute Migraine Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 91. Asia-Pacific Acute Migraine Drugs Sales Quantity by Type (2018-2023) & (K Unit)
Table 92. Asia-Pacific Acute Migraine Drugs Sales Quantity by Type (2024-2029) & (K Unit)
Table 93. Asia-Pacific Acute Migraine Drugs Sales Quantity by Application (2018-2023) & (K Unit)
Table 94. Asia-Pacific Acute Migraine Drugs Sales Quantity by Application (2024-2029) & (K Unit)
Table 95. Asia-Pacific Acute Migraine Drugs Sales Quantity by Region (2018-2023) & (K Unit)
Table 96. Asia-Pacific Acute Migraine Drugs Sales Quantity by Region (2024-2029) & (K Unit)
Table 97. Asia-Pacific Acute Migraine Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 98. Asia-Pacific Acute Migraine Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 99. South America Acute Migraine Drugs Sales Quantity by Type (2018-2023) & (K Unit)
Table 100. South America Acute Migraine Drugs Sales Quantity by Type (2024-2029) & (K Unit)
Table 101. South America Acute Migraine Drugs Sales Quantity by Application (2018-2023) & (K Unit)
Table 102. South America Acute Migraine Drugs Sales Quantity by Application (2024-2029) & (K Unit)
Table 103. South America Acute Migraine Drugs Sales Quantity by Country (2018-2023) & (K Unit)
Table 104. South America Acute Migraine Drugs Sales Quantity by Country (2024-2029) & (K Unit)
Table 105. South America Acute Migraine Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 106. South America Acute Migraine Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 107. Middle East & Africa Acute Migraine Drugs Sales Quantity by Type (2018-2023) & (K Unit)
Table 108. Middle East & Africa Acute Migraine Drugs Sales Quantity by Type (2024-2029) & (K Unit)
Table 109. Middle East & Africa Acute Migraine Drugs Sales Quantity by Application (2018-2023) & (K Unit)
Table 110. Middle East & Africa Acute Migraine Drugs Sales Quantity by Application (2024-2029) & (K Unit)
Table 111. Middle East & Africa Acute Migraine Drugs Sales Quantity by Region (2018-2023) & (K Unit)
Table 112. Middle East & Africa Acute Migraine Drugs Sales Quantity by Region (2024-2029) & (K Unit)
Table 113. Middle East & Africa Acute Migraine Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 114. Middle East & Africa Acute Migraine Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 115. Acute Migraine Drugs Raw Material
Table 116. Key Manufacturers of Acute Migraine Drugs Raw Materials
Table 117. Acute Migraine Drugs Typical Distributors
Table 118. Acute Migraine Drugs Typical Customers
List of Figures
Figure 1. Acute Migraine Drugs Picture
Figure 2. Global Acute Migraine Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Acute Migraine Drugs Consumption Value Market Share by Type in 2022
Figure 4. Triptans Examples
Figure 5. NSAIDs Examples
Figure 6. Others Examples
Figure 7. Global Acute Migraine Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Acute Migraine Drugs Consumption Value Market Share by Application in 2022
Figure 9. Hospital Pharmacies Examples
Figure 10. Drug Stores Examples
Figure 11. Global Acute Migraine Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Acute Migraine Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Acute Migraine Drugs Sales Quantity (2018-2029) & (K Unit)
Figure 14. Global Acute Migraine Drugs Average Price (2018-2029) & (USD/Unit)
Figure 15. Global Acute Migraine Drugs Sales Quantity Market Share by Manufacturer in 2022
Figure 16. Global Acute Migraine Drugs Consumption Value Market Share by Manufacturer in 2022
Figure 17. Producer Shipments of Acute Migraine Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 18. Top 3 Acute Migraine Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Top 6 Acute Migraine Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Global Acute Migraine Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 21. Global Acute Migraine Drugs Consumption Value Market Share by Region (2018-2029)
Figure 22. North America Acute Migraine Drugs Consumption Value (2018-2029) & (USD Million)
Figure 23. Europe Acute Migraine Drugs Consumption Value (2018-2029) & (USD Million)
Figure 24. Asia-Pacific Acute Migraine Drugs Consumption Value (2018-2029) & (USD Million)
Figure 25. South America Acute Migraine Drugs Consumption Value (2018-2029) & (USD Million)
Figure 26. Middle East & Africa Acute Migraine Drugs Consumption Value (2018-2029) & (USD Million)
Figure 27. Global Acute Migraine Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 28. Global Acute Migraine Drugs Consumption Value Market Share by Type (2018-2029)
Figure 29. Global Acute Migraine Drugs Average Price by Type (2018-2029) & (USD/Unit)
Figure 30. Global Acute Migraine Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 31. Global Acute Migraine Drugs Consumption Value Market Share by Application (2018-2029)
Figure 32. Global Acute Migraine Drugs Average Price by Application (2018-2029) & (USD/Unit)
Figure 33. North America Acute Migraine Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 34. North America Acute Migraine Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 35. North America Acute Migraine Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 36. North America Acute Migraine Drugs Consumption Value Market Share by Country (2018-2029)
Figure 37. United States Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Canada Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Mexico Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Europe Acute Migraine Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 41. Europe Acute Migraine Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 42. Europe Acute Migraine Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 43. Europe Acute Migraine Drugs Consumption Value Market Share by Country (2018-2029)
Figure 44. Germany Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. France Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. United Kingdom Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Russia Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Italy Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Asia-Pacific Acute Migraine Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 50. Asia-Pacific Acute Migraine Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 51. Asia-Pacific Acute Migraine Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 52. Asia-Pacific Acute Migraine Drugs Consumption Value Market Share by Region (2018-2029)
Figure 53. China Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Japan Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Korea Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. India Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Southeast Asia Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Australia Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. South America Acute Migraine Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 60. South America Acute Migraine Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 61. South America Acute Migraine Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 62. South America Acute Migraine Drugs Consumption Value Market Share by Country (2018-2029)
Figure 63. Brazil Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Argentina Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Middle East & Africa Acute Migraine Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 66. Middle East & Africa Acute Migraine Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 67. Middle East & Africa Acute Migraine Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 68. Middle East & Africa Acute Migraine Drugs Consumption Value Market Share by Region (2018-2029)
Figure 69. Turkey Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Egypt Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Saudi Arabia Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. South Africa Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Acute Migraine Drugs Market Drivers
Figure 74. Acute Migraine Drugs Market Restraints
Figure 75. Acute Migraine Drugs Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Acute Migraine Drugs in 2022
Figure 78. Manufacturing Process Analysis of Acute Migraine Drugs
Figure 79. Acute Migraine Drugs Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
